Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: A prospective study

Journal of Gastrointestinal and Liver Diseases

Volumn 23, Issue 3, 2014, Pages 273-278

  Voiosu, Theodor ^a,b   Benguş, Andreea ^a   Dinu, Roxana ^a   Voiosu, Andrei M ^a,b   Bǎlǎnescu, Paul ^b   Bǎicuş, Cristian ^a,b   Diculescu, Mircea ^b,c   Voiosu, Radu ^b   Mateescu, Bogdan ^a,b  

^a V Babes National Institute of Pathology   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c FUNDENI CLINICAL INSTITUTE   (Romania)

Author keywords

Biological markers; C reactive protein; Calprotectin; Crohn's disease; Disease activity; Inflammatory bowel disease; Mucosal healing; Noninvasive biomarkers; SIBDQ; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CALGRANULIN; ANTIINFLAMMATORY AGENT; AUTACOID; BIOLOGICAL MARKER; GASTROINTESTINAL AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COLONOSCOPY; CROHN DISEASE ACTIVITY INDEX; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FECES ANALYSIS; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; MALE; MAYO SCORE; MUCOSA INFLAMMATION; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SHORT INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORE; TREATMENT OUTCOME; AREA UNDER THE CURVE; CHEMISTRY; COLON; DRUG EFFECTS; FECES; ILEUM; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; INTESTINE MUCOSA; METABOLISM; MIDDLE AGED; PATHOLOGY; PREDICTIVE VALUE; PSYCHOLOGY; RECEIVER OPERATING CHARACTERISTIC; ROMANIA; YOUNG ADULT;

ADULT; ANTI-INFLAMMATORY AGENTS; AREA UNDER CURVE; BIOLOGICAL MARKERS; COLON; COLONOSCOPY; FECES; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; ILEUM; INFLAMMATION MEDIATORS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; REMISSION INDUCTION; ROC CURVE; ROMANIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906860277     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.15403/jgld.2014.1121.233.thv     Document Type: Article

References (25)

1. Frøslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412-422.
2. Af Bjorkesten CG, Nieminen U, Sipponen T, Turunen U, Arkkila P, Färkkilä M. Mucosal healing at three months predicts long-term endoscopic remission in antiTNF treated luminal Crohn's disease. Scand J Gastroenterol 2013;48:543-551.
3. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-1301.
4. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011;141:1194-1201.
5. Meucci G, Fasoli R, Saibeni S, et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm Bowel Dis 2012;18:1006-1010.
6. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965-990.
7. Peyrin-Biroulet L, Reinisch W, Colombel JF, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial. Gut 2014;63:88-95.
8. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011;140:1817-1826.
9. De Vos M, Louis EJ, Jahnsen J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis 2013;19:2111-2117.
10. Faubion WA Jr, Fletcher JG, O'Byrne S, et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol 2013;108:1891-1900.
11. af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease. Scand J Gastroenterol 2012;47:528-537.
12. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc 2006;63:433-442.
13. http://www.stard-statement.org/ Accessed on 10.04.2014.
14. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis 2013;7:982-1018.
15. Sydora MJ, Sydora BC, Fedorak RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis 2012;6:207-214.
16. Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn's Relapse Prevention Trial. Am J Gastroenterol 1996;91:1571-1578.
17. Schoepfer AM, Vavricka S, Zahnd-Straumann N, Straumann A, Beglinger C. Monitoring inflammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis 2012;6:412-418.
18. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn'sdisease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162-169.
19. Jones J, Loftus EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218-1224.
20. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis 2012;18:2218-2224.
21. Jauregui-Amezaga A, López-Cerón M, Aceituno M, et al. Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study. Inflamm Bowel Dis 2014;20:1187-1193.
22. Mao R, Xiao YL, Gao X, et al. Fecal calprotectin in predicting relapse of inflammatory bowel diseases: a meta-analysis of prospective studies. Inflamm Bowel Dis 2012;18:1894-1899.
23. Lemann M, Colombel JF, Grimaud JC, et al. Fecal calprotectin and high sensitivity C-reactive protein levels to predict mucosal healing in patients with Crohn's disease. A subanalysis of the STORI study. Gut 2010;59(Suppl III):A80.
24. Xiang JY, Ouyang Q, Li GD, Xiao NP. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008; 14: 53-57.
25. D'Inca R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis 2007; 22:429-437.